Bioventus Inc (NAS:BVS)

Q2 2026 Bioventus Inc Earnings Call Transcript

Aug 5, 2026 / 12:30 PM GMT

Release Date Price: $15.26 (+13.71%)

Transcript 10-Q8-K

Key Points

Positve

Bioventus Inc (BVS) delivered solid Q2 results with 4% revenue growth, led by strong double-digit growth in its pain treatments business.
The HA franchise, particularly Durolane, continues to be a durable strength, consistently growing well above the market and driving volume gains.
Adjusted EBITDA margin expanded to 23% despite increased investments, demonstrating enhanced earnings power and operational discipline.
The company achieved a key financial milestone by reducing net leverage to below 2 times, with expectations to be below 1.5 times by year-end.
Strong cash flow generation enabled the company to repay $24 million of debt in Q2, bringing total debt repayment for the year to $46 million.
Leading indicators in growth drivers like PRP, PNS, and ultrasonics show positive traction, including increased capital placements, surgeon adoption, and new account wins.
The company reaffirmed its full-year 2026 guidance, expecting revenue acceleration in the second half by over 300 basis points compared to the first half.

Negative

Surgical solutions revenue declined 5% year-over-year due to challenging prior year comparisons and timing shifts of approximately $2 million in ultrasonics capital placements and international orders.
Restorative therapies revenue declined 2% due to a shift in customer mix, specifically with fewer Medicare orders, and a difficult prior year comparison.
Adjusted gross margin decreased by 90 basis points year-over-year, primarily due to higher freight costs and product mix.
International revenue was slightly lower year-over-year due to the timing of distributor orders, although the company expects strong double-digit growth in the second half.
The company took proactive actions in the BGS channel that had a temporary negative impact on performance, though it expects acceleration in the back half.
Adjusted EPS growth was modest at $0.22 per share, up only $0.01 from the prior year, impacted by a higher effective tax rate due to the removal of the valuation allowance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BVS.OQ - Bioventus Inc.
Q2 2026 Bioventus Inc Earnings Call
Aug 05, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and thank you for standing by, my name is Regina, and I will be your conference operator today.

At this time, I'd like to welcome everyone to the Bioventis Inc.

Second quarter 2026 earnings conference call.

All lines have been placed on mute to prevent any background noise.

After the speaker's remarks, there will be a question-and-answer session.

If you'd like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad to withdraw your question, pressar 1 again.

I'd now like to hand you today.

Conference over to Dave Crawford, please go ahead.

Thanks, Virginia, and good morning everyone, and thanks for joining us.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.